To assess the clinical effectiveness of betablocker therapy in individuals with heart failure (HF) and chronic lung disease and of angiotensin-converting enzyme inhibitors (ACE-Is) and angiotensin II receptor blockers (ARBs) in individuals with HF and chronic kidney disease. DESIGN: Retrospective cohort study. SETTING: Community. PARTICIPANTS: Individuals with HF with reduced ejection fraction (HFrEF) or HF with preserved ejection fraction (HFpEF). METHODS: We undertook separate new-user cohort studies to assess the effectiveness of beta-blocker therapy in treating HF and chronic lung disease and ACE-Is and ARBs in treating HF and chronic kidney disease (CKD). Individuals with a chronic lung disease diagnosis were included in the group with HF and chronic lung disease (International Classification of Diseases, Ninth Revision, codes 490-496, 518). Individuals with an estimated glomerular filtration rate less than 60 mL/min per 1.73 m 2 were included in the group with HF and CKD. The clinical outcomes of interest were death from any cause, hospitalization for HF, and hospitalization for any reason. We fitted pooled logistic marginal structural models using inverse probability weighting, stratified according to HF type. RESULTS: For individuals with HFrEF with chronic lung disease, beta-blocker therapy was protective against death (relative risk (RR) = 0.58, 95% confidence interval (CI) = 0.44-0.77) and hospitalization for HF (RR = 0.78, 95% CI = 0.60-1.00). For those with HFpEF, no statistically significant associations between beta-blocker therapy use and any of the outcomes were observed. We found ACE-I and ARB use to be protective against all three outcomes of interest in individuals with HFrEF (death from any cause: RR = 0.60, 95% 0.40-0.91; hospitalization for HF: RR = 0.43, 95% CI = 0.28-0.67; hospitalization for any reason: RR = 0.63, 95% CI = 0.45-0.89, respectively) and those with HFpEF (death from any cause: RR = 0.52, 95% CI = 0.33-0.81; hospitalization for HF: RR = 0.35, 95% CI = 0.18-0.68; hospitalization for any reason: RR = 0.67, 95% CI = 0.47-0.95). CONCLUSION: Large observational studies may allow for identification of important subgroups of individuals with HF that might benefit from existing treatment approaches. Our findings may also better inform the design of more-definitive future observational studies and randomized trials.
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Key words: multimorbidity; heart failure; comorbidity; lung disease; kidney disease C omorbidities in individuals with heart failure (HF) can pose diagnostic and treatment challenges, substantially increasing the complexity of caring for these individuals. 1 Because practitioners must manage not just a single condition but multiple conditions simultaneously, 2 caution is required in applying clinical guidelines to the care of individuals with comorbidities, especially older adults, because this could result in undesirable outcomes, including adverse interactions between drugs and diseases. 3 Multimorbidity greatly increases the risk of hospitalization and death in individuals with HF. [4] [5] [6] [7] Efforts to reduce these risks are particularly challenging given the limited data available to guide clinical practice.
Older adults with HF frequently have chronic lung disease and CKD, 8 and these conditions are among the comorbid conditions that confer the highest risks of excess mortality and morbidity. 9 Certain HF-related treatments raise special concerns for individuals with HF with concomitant chronic lung disease or CKD. For example, beta-blockers can aggravate bronchospastic symptoms in individuals with reactive airway disease, and it has been recommended that these agents be used cautiously in such individuals.
1 CKD frequently complicates HF because of poor renal perfusion and preexisting intrinsic renal disease and as a result of the effects of medications used to treat HF. Renal function may worsen with use of ACE-Is in individuals with HF, although the changes are generally reversible. 10 Although ACE-Is are the first choice for inhibition of the renin-angiotensin system in individuals with HF with reduced left ventricular ejection fraction (HFrEF), angiotensin II receptor blockers (ARBs) are considered to be a reasonable alternative because they have an adverse effect profile similar to that of ACE-Is. 1 In the present study, we examined a set of questions relating to the treatment of HF in the setting of two common comorbidities. Our objectives were to assess the clinical effectiveness of beta-blocker therapy in individuals with HF and chronic lung disease and of ACE-Is or ARBs in individuals with HF and CKD. In each case, we sought to examine the effects of these therapies separately in individuals with HFrEF and HF with preserved ejection fraction (HFpEF) treated in representative community-based real-world populations.
METHODS

Setting
The source population included members from four participating health plans within the Cardiovascular Research Network (CVRN) from 2005 through 2008. 11 Sites included Kaiser Permanente Northern California, Kaiser Permanente Colorado, Kaiser Permanente Northwest, and Fallon Health. Institutional review boards at participating sites approved the study, and waiver of consent was obtained because of the nature of the study.
Participants
We identified individuals with diagnosed HF based on having been hospitalized with a primary discharge diagnosis of HF or having three or more ambulatory visits coded for HF with at least one visit being with a cardiologist between January 2005 and December 2008 using International Classification of Diseases, Ninth Edition (ICD-9) codes. Previous studies have shown a positive predictive value of greater than 95% for admissions with a primary discharge diagnosis of HF based on these codes when compared with chart review and Framingham clinical criteria. [12] [13] [14] We ascertained information on quantitative and qualitative assessments of left ventricular systolic function from the results of echocardiograms, radionuclide scintigraphy, other nuclear imaging modalities, and left ventriculography test results available from site-specific databases complemented by manual chart review. We defined preserved ejection fraction as a reported left ventricular ejection fraction of 50% or greater or based on a physician's qualitative assessment of preserved or normal systolic function. 15 Reduced ejection fraction was defined as a reported left ventricular ejection fraction of 40% or less or based on a physician's qualitative assessment of moderate, moderate to severe, or severe systolic dysfunction.
We identified two HF subgroups of special interest: individuals with HF and chronic lung disease and individuals with HF and CKD.
We included individuals with a chronic lung disease diagnosis at or before the date of inclusion of the individual in the study population in the group with HF and chronic lung disease (ICD-9 codes 490-496, 518). We excluded individuals with a history of organ transplant at baseline and those who had received any beta-blocker therapy within up to 5 years before the index date, because we were specifically interested in the clinical effectiveness of beta-blocker therapy in individuals with HF and chronic lung disease who were newly initiated on therapy. To ensure an adequate baseline period to characterize participants, we excluded individuals with fewer than 12 months of continuous health plan membership and pharmacy drug benefit before the index date.
We included individuals with an estimated glomerular filtration rate (eGFR) of less than 60 mL/min per 1.73 m 2 according to laboratory results available on or before the date of inclusion of the individual in the study population in the group with HF and CKD. We excluded individuals with a history of organ transplant or dialysis at study entry, defined as up to 5 years before and including the index date, those with an eGFR of greater than or equal to 60 mL/min per 1.73 m 2 at baseline and during follow-up using the Chronic Kidney Disease Epidemiology Collaboration equation based on outpatient, nonemergency department serum creatinine measures, 16 and those missing eGFR values or blood hemoglobin measurements at baseline. Similar to the approach described previously for outcomes associated with beta-blockers in individuals with HF and chronic lung disease, we excluded individuals who received any ACE-I or ARB therapy within up to 5 years before the index date to focus on the clinical effectiveness of ACE-I or ARB therapy in individuals with HF and CKD who were newly initiated on therapy. To ensure an adequate baseline period to characterize the participants, we excluded individuals with less than 12 months of continuous health plan membership and pharmacy drug benefit before the index date.
Study Design: Exposures, Follow-Up, and Outcomes
For each corresponding dyad, we ascertained use of betablocker, ACE-I, or ARB therapy from filled outpatient prescriptions from pharmacy databases. We employed a "new user" design to eliminate prevalent user bias by restricting the analysis to persons under observation at the start of treatment. 17 We characterized time-varying exposure to therapy using previously validated methods based on estimated days' supply information per dispensed prescription and refill patterns found in health plan pharmacy databases. 18 Briefly, for any two consecutive prescriptions, we examined the time between the projected end date of the first prescription and the date of the next filled prescription. Because dose adjustment is not uncommon, we allowed a "grace period" of 30 days between prescriptions. If the time between the projected end date of the first prescription and the fill date of the next prescription was 30 days or less, we considered that individual to be continuously receiving the therapy of interest. If the refill interval was more than 30 days, we considered the individual off therapy starting the day after the projected end date of the first prescription until the date of the next filled prescription, if any. If a refill occurred earlier than the predicted end of days' supply, then any overlap in days' supply was not added to the end of the next prescription.
Follow-up occurred from the index date through December 31, 2008, for a maximum of 4 years. Median follow-up was 1.6 years (interquartile range (IQR) 0.6-2.8 years) in the group with HF and chronic lung disease and 1.1 years (IQR 0.3-2.2 years) in the group with HF and CKD. The clinical outcomes of interest were death from any cause, hospitalization for HF, and hospitalization for any reason. Subjects were censored if they disenrolled from the health plan, received an organ transplant, initiated chronic dialysis, or reached the end of study follow-up. Deaths were identified from hospital and billing claims databases, administrative health plan databases, state death certificate registries, and Social Security Administration files, as available at each site. These approaches have yielded greater than 97% vital status information in prior studies.
12,13
Covariates
We ascertained information on coexisting illnesses based on diagnoses or procedures using relevant ICD-9 codes, laboratory results, and filled outpatient prescriptions from health plan hospitalization discharge, ambulatory visit, laboratory, and pharmacy databases, as well as site-specific cancer registries. 19 We defined prevalent HF as having any hospitalization or ambulatory HF diagnosis during a lookback period of up to 5 years before the date of the diagnosis that led to inclusion in the study cohort.
We ascertained available ambulatory results for baseline and time-updated systolic and diastolic blood pressure, serum low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein (HDL-C) measurements, eGFR, dipstick proteinuria, and blood hemoglobin level. We also collected baseline and time-updated information on receipt of other selected medications, including aldosterone antagonists, calcium channel blockers, digoxin, loop diuretics, thiazide diuretics, nitrates, statins, other lipid-lowering drugs, anticoagulants, and antiplatelets.
Statistical Analysis
Analyses were conducted using SAS version 9.3 (SAS Institute, Inc., Cary, N.C.). We compared the baseline characteristics of participants who did and did not initiate the therapies of interest using analysis of variance or the relevant nonparametric test for continuous variables and chisquare tests for categorical variables.
For each combination of conditions and associated therapy of interest, we fitted pooled logistic marginal structural models (MSMs) 20 stratified according to HFrEF or HFpEF at baseline. We first constructed our analytical dataset based on a directed acyclic graph of exposure and outcome relationships based on the published literature. Each participant's follow-up time was then divided into 30-day intervals starting on their index date. Exposures, outcomes, and covariates were then organized into proper time order within and between these time intervals. Next, we calculated inverse probability weights (IPWs) to adjust for potential baseline and time-dependent confounders. 21 We separately calculated exposure and censoring IPWs and then multiplied them to determine the final summary IPW for each participant. We constructed three models to characterize exposure to the therapy of interest to facilitate generation of weights: probability of exposure at start of follow-up, probability of exposure given previously not being exposed in the prior period, and probability of exposure given previously being exposed in the prior period. One censoring model was used to capture censoring due to disenrollment from the health plan or end of administrative study follow-up. After evaluation of the distribution, the final summary IPW was truncated at 2% and 98% for model stability. Our modeling approach was an "as treated" MSM analysis evaluating the effect of exposure to the therapy of interest on outcomes, with incorporation of IPWs to account for baseline and time-dependent confounders, as well as splines set to 1%, 25%, 50%, 75%, and 99% of overall cohort follow-up time to adjust for the potential effect of time.
RESULTS
Of the 2,414 participants with a history of chronic lung disease and no prior beta-blocker use at study entry, 986 had HFrEF, and 1,428 had HFpEF. Details of cohort assembly are provided in Supplementary Figure S1 .
Participants with HFrEF who used beta-blockers were considerably younger than those with no use during follow-up (mean age 69.0 vs 77.7; P < .001) ( Table 1) . They were less likely to have previous percutaneous coronary intervention, atrial fibrillation or flutter, ventricular tachycardia or fibrillation, mitral or aortic valvular disease, a pacemaker, hospitalized bleeds, dementia, and falls. Individuals with HFrEF who used beta-blockers also had higher eGFR, hemoglobin, and systolic and diastolic blood pressure levels (Supplementary Table S1 ). In contrast, individuals with HFrEF who used beta-blockers were less likely to use loop diuretics, nitrates, antiplatelet agents, or anticoagulants (Supplementary Table S2 ). In an MSM analysis of individuals with HFrEF with chronic lung disease that accounted for potential baseline and timedependent confounders, beta-blocker therapy was protective against death from any cause (hazard ratio (HR) = 0.58, 95% CI = 0.44-0.77) and hospitalization for HF (HR 0.78, 95% CI = 0.60-1.00), but there was no statistically significant association observed with hospitalization from any cause (Figure 1) .
Participants with HFpEF who used beta-blockers were significantly younger than those with no use (mean age 73.2 vs 75.6; P < .001) ( Table 1) . They were less likely to have prior acute myocardial infarction, ischemic stroke or Table S1 ) and less likely to use aldosterone receptor antagonists, digoxin, loop diuretics, and anticoagulants (Supplementary Table S2 ). In contrast to results in participants with HFrEF, in eligible participants with HFpEF and chronic lung disease, there were no statistically significant associations between beta-blocker therapy use and any of the outcomes of interest in MSM analyses (Figure 1 ). Of the 1,492 participants with CKD and no prior ACE-I or ARB use, 482 had HFrEF, and 1,010 had HFpEF (Supplementary Figure S2) .
Participants with HFrEF who used ACE-Is or ARBs were less likely than nonusers to have had a prior acute myocardial infarction, percutaneous coronary intervention, ischemic stroke or transient ischemic attack, ventricular tachycardia or fibrillation, implantable cardioverter defibrillator, or liver disease (Table 2) . Participants who used ACE-Is or ARBs had higher eGFR levels and were less likely to have dipstick proteinuria (Supplementary  Table S3 ). They were also less likely to use aldosterone receptor antagonists, calcium channel blockers, loop diuretics, or nitrates (Supplementary Table S4 ). In MSM models of eligible participants with HFrEF with concomitant CKD that adjusted for baseline and time-dependent confounders, ACE-I or ARB therapy was protective against death from any cause (HR = 0.60, 95% CI = 0.40-0.91), hospitalization for HF (HR = 0.43, 95% CI = 0.28-0.67), and hospitalization for any reason (HR = 0.63, 95% CI = 0.45-0.89) (Figure 2) .
Participants with HFpEF who used ACE-Is or ARBs were less likely to be female and to have a history of atrial fibrillation or flutter, ventricular tachycardia or fibrillation, hospitalized bleeds, and cancer than nonusers (Table 2) . Participants with ACE-I or ARB use had higher eGFR and diastolic blood pressure and lower LDL-C levels and were less likely to have dipstick proteinuria (Supplementary  Table S3 ). They were also less likely to use calcium channel blockers and nitrates and more likely to use thiazide diuretics (Supplementary Table S4 
DISCUSSION
In community-based individuals with HFrEF and chronic lung disease, beta-blocker therapy was associated with lower risk of death from any cause and hospitalization, but there were no statistically significant associations between beta-blocker use and any of the outcomes of interest in those with HFpEF and chronic lung disease. In participants with HFpEF or HFrEF and CKD, ACE-I or ARB use was independently associated with lower risk of death from any cause, hospitalization for HF, and hospitalization for any reason.
The findings of two recent metaanalyses are intriguing in relation to our results. One evaluated the effect of betablockers on mortality and morbidity in individuals with HFpEF. 22 Observational studies included in this metaanalysis suggested a favorable association between receipt of beta-blockers and all-cause mortality but not HF-related hospitalization. No subgroup analyses were performed relevant to individuals with specific comorbidities, and potential time-dependent confounding was not addressed. The Figure 1 . Effect of beta-blockers on risks of death from any cause, hospitalization for heart failure, and hospitalization from any cause in adults with heart failure and chronic lung disease, stratified according to left ventricular ejection fraction. .09
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Other thromboembolic event other metaanalysis of randomized controlled trials assessing the efficacy of inhibition of the renin-angiotensinaldosterone system in HF suggested that the beneficial effects decreased with increasing mean left ventricular ejection fraction for outcomes including mortality and HF hospitalization. 23 Nevertheless, although no benefit of reninangiotensin-aldosterone system inhibition on all-cause mortality was observed above a mean ejection fraction of 50%, a significant benefit for HF-related hospitalization was observed (RR = 0.88, 95% CI = 0.80-0.97). Again, no subgroup analyses were performed relevant to individuals with specific comorbidities.
Our study has several strengths and limitations. Insured populations receiving care in the healthcare delivery systems relevant to our study may not be fully representative of all people with HF. The breadth of geographic and demographic diversity and the community-based nature of healthcare delivery counterbalanced this limitation, suggesting that the findings are highly generalizable to individuals with HF in real-world practice settings in relation to the treatments they receive and the effectiveness of these treatments. In addition, individual diagnoses of HF were not adjudicated through medical record abstraction and expert review, although prior studies in our population have shown a high positive predictive value for the approach we used to identify individuals with HF. 12, 13 We also used quantitative and qualitative assessments of left ventricular systolic function to characterize individuals as having HFrEF versus HFpEF. CKD diagnoses were based on eGFR, but diagnoses of chronic lung disease were based on diagnosis codes and were not validated.
Small sample sizes in subgroups of interest limited the precision of our estimates of effect. We also did not study individuals with HF with an EF of 41% to 49%, of whom there were few. These individuals, who fall into a "borderline," "intermediate," or "midrange" group, may constitute a separate group with regard to characteristics, pathophysiology, and treatment. 24 Our new-user study design addressed the problem of prevalent user bias that plagues many observational studies of treatment effectiveness when information about baseline medication use is lacking, 17 although an inherent limitation of observational studies is the potential for residual confounding and selection bias. Of particular concern is healthy user bias, which we attempted to mitigate through our analytical approach, although there still may have been residual confounding, because users of betablockers, ACE-Is, or ARBs had a lower comorbidity burden than nonusers. Strategies to address healthy user bias include having an active control, 25 which was not possible in these studies. We combined this design approach with marginal structural modeling and inverse probability weighting to address potential time-dependent confounding, overcoming the limitations of several commonly used methods such as propensity score matching and Cox regression. 26 Trials of treatments for HF have excluded the types of individuals most commonly presenting with this condition, particularly older adults and those with high burdens of comorbidity, [27] [28] [29] posing an ongoing challenge for clinical decision-making in the growing numbers of these high-risk individuals with HF. 3, 5, 8, 30 In addition, the current non-evidence-based approach to the care of individuals with HFpEF is extremely frustrating. 31 The imperative to address this situation has never been greater, because the majority of older adults who present with a new diagnosis of HF have HFpEF. 32 With the aging of the U.S. population, it is likely that the numbers of individuals with this form of HF will increase dramatically over the coming decades, with many if not most having additional chronic conditions. The Figure 2 . Effect of angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker therapy on risk of death from any cause, hospitalization for heart failure, and hospitalization for any reason in adults with heart failure and chronic kidney disease, stratified according to left ventricular ejection fraction.
findings of our efforts suggest that large observational studies may allow for the identification of important subgroups of the population with HF that might benefit from existing treatment approaches and inform the design of more-definitive future randomized controlled trials.
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